Boris Minev, MD
Dr. Minev has a track record of excellence in cellular therapy and biological based approaches. Prior to his appointment at UCSD in Neurosurgery and Moores Cancer Center, Dr. Minev was involved in development of Melacine, the first cancer vaccine to receive regulatory approval in the Western World. Dr. Minev has published numerous research findings with Medistem and is currently using ERC as a gene-delivery vector for treatment of glioma.
Kyle Chan, Ph.D.
Dr. Chan is an accomplished scientist who started numerous biotechnology companies. He has served as Senior Director of Translational Research at Celgene corporation, leading development of numerous products through the FDA regulatory pathway. Dr. Chan has a Ph.D. from the University of Illinois at Champaign-Urbana and was also a Post-Doctoral Fellow at the University of California, San Diego.
Alan Lewis
Dr. Lewis is currently a Management Consultant to various specialty biopharmaceutical companies. He was most recently President, CEO and Chariman of Ambit BioSciences, and previously President and CEO of the Juvenile Diabetes Research Foundation and President, CEO and Director of Novocell, Inc. Prior to Novocell, Dr. Lewis served as CEO and Director of Signal Pharmaceuticals before its acquisition by Celgene, a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for cancer and immunological diseases, after which he served as President of the Signal Research Division at Celgene. Before joining Signal, Dr. Lewis held the position of Vice President of Research at Wyeth-Ayerst, where he spent 15 years leading research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. Dr. Lewis currently serves as a Director of BioMarin Pharmaceutical, Inc., and BIOCOM. He holds a Ph.D. in pharmacology from the University of Wales in Cardiff and completed his postdoctoral training at Yale University.
Hugh S. Taylor, M.D.
A Professor of Obstetrics, Gynecology and Reproductive Science, and Director of Reproductive Endocrinology and Infertility at the Yale University School of Medicine in New Haven, Connecticut. He is also Professor of Molecular, Cellular and Developmental biology at Yale University. He is a board certified specialist in Obstetrics/Gynecology and in Reproductive Endocrinology. Dr. Taylor received his undergraduate training at Yale University and received his medical degree from the University of Connecticut School Of Medicine. He completed his residency in Obstetrics and Gynecology at Yale. His postdoctoral training included a fellowship in Reproductive Endocrinology and Infertility as well as a fellowship in Molecular Biology, both at Yale.
Dr. Taylor is a recipient of eight National Institutes of Health research grants and directs The Yale Center for Reproductive Biology. His research centers on stem cells, uterine development, implantation, endometriosis and menopause. Dr. Taylor has published more than 200 articles in leading medical journals. He is the Editor-In-Chief of Reproductive Sciences.
He serves on several editorial boards and as a reviewer for numerous scientific journals and is a frequently invited as a speaker at national and international medical meetings. Dr. Taylor has received numerous awards including the National Institutes of Health Physician’s Scientist Award and the Society for Gynecologic Investigation President Achievement Award. He has also served as the academic mentor of numerous trainees and has twelve times been awarded the Society of Gynecologic Investigation President Presenter’s Award for this training. Dr. Taylor is on the council of the Society for Gynecologic Investigation and was clinical director of the Society for Assisted reproductive technology.